Showing 5181-5190 of 5621 results for "".
- Notal Vision Diagnostic Clinic Reports Completion of 6 Million ForeseeHome AMD Home-Monitoring Testshttps://modernod.com/news/notal-vision-diagnostic-clinic-reports-completion-of-6-million-foreseehome-amd-home-monitoring-tests/2476750/Notal Vision announced the completion of 6 million patient tests performed with ForeseeHome, the first FDA-cleared home-monitoring device for patients with intermediate dry age-related macular degeneration (AMD) at risk for developing wet AMD, according to a company news release. ForeseeHo
- Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseaseshttps://modernod.com/news/trefoil-therapeutics-raises-28-million-series-a-to-advance-engineered-fgf-1-for-the-treatment-of-corneal-diseases/2476735/Trefoil Therapeutics announced it raised $28 million in an oversubscribed Series A financing. The company is developing novel engineered fibroblast growth factor-1 proteins (eFGF-1) as a regenerative pharmacologic therapy to treat serious corneal endothelial diseases and epithelial disorders.
- Clerio Vision Acquires Manufacturer of Extreme H2O Contact Lenseshttps://modernod.com/news/clerio-vision-acquires-manufacturer-of-extreme-h2o-contact-lenses/2476732/Clerio Vision announced that it has acquired Hydrogel Vision Corporation (HVC), a manufacturer and distributor of contact lenses. Terms of the deal were not disclosed. HVC, founded in 2002, is best known for its Extreme H2O product line and its multiple differentiated offerings that
- US Scraps Proposal to Curb Drug Rebates Paid to Pharmacy Benefit Managershttps://modernod.com/news/us-scraps-proposal-to-curb-drug-rebates-paid-to-pharmacy-benefit-managers/2476729/The US government pulled the plug on plans designed to reduce drug prices by limiting rebates paid by drugmakers to pharmacy benefit managers (PBMs). White House spokesman Judd Deere said on Thursday that “based on careful analysis and thorough consideration, the President has decided to wi
- BioTime Initiates Dosing in Phase 1/2a Clinical Study of OpRegen for Treatment of Dry AMDhttps://modernod.com/news/biotime-initiates-dosing-in-phase-1-2a-clinical-study-of-opregen-for-treatment-of-dry-amd/2476722/BioTime announced that it has dosed its first patient with the Orbit Subretinal Delivery System (Orbit SDS) as well as with a new thaw-and-inject formulation of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, in its ongoing phase 1/2a clinical study for the treatment o
- Double-Barreled Biologic for Diabetic Retinopathy Emerginghttps://modernod.com/news/double-barreled-biologic-for-diabetic-retinopathy-emerging/2476720/Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF), the only pathway for which there are approved therapies, and are developing treatments that can be administered less often, according to a
- Prevent Blindness Focus On Eye Health National Summithttps://modernod.com/news/prevent-blindness-focus-on-eye-health-national-summit/2476719/Prevent Blindness will host the 8th Annual Focus on Eye Health National Summit at the National Press Club in Washington DC on Wednesday, July 17 at 7:30 am ET. The theme of the event is “A Lifetime of Vision” and will feature keynote speaker Bill Barkley, deaf-blind adventure
- Horizon Therapeutics Submits Biologics License Application for the Treatment of Active Thyroid Eye Diseasehttps://modernod.com/news/horizon-therapeutics-submits-biologics-license-application-for-the-treatment-of-active-thyroid-eye-disease/2476716/Horizon Therapeutics announced that it has submitted a biologics license application (BLA) to the FDA for its investigational medicine teprotumumab for the treatment of active thyroid eye disease (TED). Teprotumumab has breakthrough therapy, orphan drug and fast track designations from the FDA. H
- Bausch + Lomb Announces US Launch Of Ocuvite Eye Performance Vitaminshttps://modernod.com/news/bausch-lomb-announces-us-launch-of-ocuvite-eye-performance-vitamins/2476714/Bausch + Lomb announced the US launch of Ocuvite Eye Performance vitamins, which were formulated with seven nutrients that help strengthen the macula. The nutrients protect the eye from stressors such as sun light and blue light emitted from digital devices. These nutrients include lutein
- Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjectorhttps://modernod.com/news/clearside-biomedical-announces-license-agreement-with-aura-biosciences-for-suprachoroidal-space-microinjector/2479566/Clearside Biomedical announced its entry into a worldwide licensing agreement with Aura Biosciences for the use of Clearside’s Suprachoroidal Space (SCS) Microinjector to deliver Aura’s proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choro